The CEO of a $50 billion company explains why big-time dealmaking has dropped

For big drugmakers that want to grow their business, acquiring smaller companies with one or two products is often a surefire way to make sure that happens.

But in the past few years, we’ve seen a slowdown in M&A, with acquisitions in the first quarter of 2017 down 35% from the same period two years ago.

Flemming Ornskov, the CEO of $US50 billion drugmaker Shire which had one of the biggest pharma mergers in recent history with the $US32 billion acquisition of Baxalta at the very start of 2016, said he knows there’s been less M&A than usual.

Read more